ERBB2 and breast cancer: Phase IB/II Open‐label Single‐Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor‐Positive and HER2‐positive Metastatic Breast Cancer